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Abstract
Background
Primaquine is recommended by the World Health Organization (WHO) for radical treatment
of Plasmodium vivax malaria. This drug is known to provoke acute hemolytic anemia in indi-
viduals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Due to lack of data on
G6PD deficiency, the use of primaquine has been limited in Africa. In the present study,
G6PD deficiency was investigated in blood donors of various ethnic groups living in Nouak-
chott, a P. vivax endemic area in Mauritania.
Methodology/Principal findings
Venous blood samples from 443 healthy blood donors recruited at the National Transfusion
Center in Nouakchott were screened for G6PD activity using the CareStart G6PD deficiency
rapid diagnostic test. G6PD allelic variants were investigated using DiaPlexC G6PD geno-
typing kit that detects African (A-) and Mediterranean (B-) variants. Overall, 50 of 443
(11.3%) individuals (49 [11.8%] men and 1 [3.7%] woman) were phenotypically deficient.
Amongst men, Black Africans had the highest prevalence of G6PD deficiency (15 of 100
[15%]) and White Moors the lowest (10 of 168, [5.9%]). The most commonly observed
G6PD allelic variants among 44 tested G6PD-deficient men were the African variant A-
(202A/376G) in 14 (31.8%), the Mediterranean variant B- (563T) in 13 (29.5%), and the
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Betica-Selma A- (376G/968C) allelic variant in 6 (13.6%). The Santamaria A- variant (376G/
542T) and A variant (376G) were observed in only one and two individuals, respectively.
None of the expected variants was observed in 8 (18.2%) of the tested phenotypically
G6PD-deficient men.
Conclusion
This is the first published data on G6PD deficiency in Mauritanians. The prevalence of phe-
notypic G6PD deficiency was relatively high (11.3%). It was mostly associated with either
African or Mediterranean variants, in agreement with diverse Arab and Black African origins
of the Mauritanian population.
Introduction
Malaria remains a major public health burden in Mauritania with two-thirds of the population
at risk. In the northern Saharan zone of the country, including Nouakchott, the capital city,
malaria is predominantly caused by Plasmodium vivax [1, 2], whereas in the southern Sahelian
zone, almost all malaria cases are due to Plasmodium falciparum [3, 4].
Plasmodium vivax infection is characterized by the occurrence of relapses several weeks or
even months after the primary infection due to the persistent quiescent liver forms (hypno-
zoites). Radical cure of P. vivax malaria requires the elimination of both the blood stage para-
sites and hypnozoites. Primaquine, an 8-aminoquinoline, has long been the only available and
effective drug capable of killing hypnozoites and, therefore, of preventing relapses [5]. Tafeno-
quine (Krintafel), another 8-aminoquinoline with a hypnozoicidal activity, has recently been
approved by the United States Food and Drug Administration [6]. Despite their effectiveness
in eliminating hypnozoites, 8-aminoquinolines may cause dose-dependent oxidant hemolysis
in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals [7, 8].
G6PD deficiency is the most common genetic enzyme disorder in humans with 400 million
affected persons worldwide. Currently, 217 mutations on the g6pd gene have been described
and genetically characterized [9, 10]. In sub-Saharan Africa, the most frequent G6PD variants
are the wild-type G6PD B, the non-deficient variant G6PD A, and the deficient variant G6PD
A- [11]. The variant G6PD A results from the point mutation A376G whereas the deficient var-
iant G6PD A- is characterized by the combination of A376G mutation and one of the following
mutations: G202A, A542T, G680T, or T968C. In North Africa, g6pd gene with a point muta-
tion (C563T), known as the “Mediterranean variant (B-),” also occurs [12]. The G6PD A- vari-
ant is often associated with mild to moderate hemolytic anemia, as compared to other G6PD
variants, although fatal reactions to primaquine have been recorded in a limited number of
patients [13]. The Mediterranean variant often results in a more clinically severe hemolytic
reaction following primaquine therapy and predisposes individuals to favism [14]. Because of
its X-linked mode of inheritance, G6PD deficiency affects men more frequently than women.
Current G6PD deficiency diagnostic methods include the fluorescent spot test [15], spec-
trophotometric assay, also called enzyme activity assay [16], and cytochemical assay [17].
Although these techniques are reliable to identify G6PD deficiency, they are time consuming
and require sophisticated laboratory equipment and skilled personnel to perform the tests,
making them difficult to use in low-resource settings [18]. Recently, several qualitative rapid
diagnostic tests for screening this enzymatic disorder have been developed [19]. These provide
the results rapidly (within 10–15 min), work in a wide range of ambient temperature, use
G6PD deficiency and associated genetic variants in Mauritania
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small amounts of fresh whole capillary blood, and are not costly, compared to conventional
diagnostic tests performed in well-equipped laboratories [19, 20, 21].
Since 2014, primaquine is recommended by the Mauritanian Ministry of Health for the
radical treatment of P. vivax malaria in patients with normal G6PD activity [22]. Before prima-
quine can be administered to a patient for radical treatment of P. vivax malaria, screening for
G6PD activity is required because primaquine is contraindicated in patients with G6PD defi-
ciency. However, in almost all health facilities in the country, the G6PD status of P. vivax-
infected malaria patients is not or cannot be determined at present, leading to non-use of pri-
maquine. Moreover, there is no recent database on G6PD status in Mauritania. Therefore, the
objective of this study was to assess the prevalence of different variants of G6PD deficiency in
Mauritanian blood donors of different ethnic origins in Nouakchott, where P. vivax is
endemic. The obtained data will be useful for decision making on the possible need for routine
G6PD deficiency testing as part of P. vivax malaria control and elimination in the country.
Methods
Study site
The study was conducted in 2016 at the National Blood Transfusion Center (CNTS) in Nouak-
chott (Fig 1). The Nouakchott that contributes to a quarter of the total population (1,043,177) of
Mauritania reflects the diverse ethnicity of the country [23]. The two major ethno-linguistic
groups are the Moors (consisting of white and black Moors) and black Africans (including Pular,
Soninke, and Wolof). White and black Moors share the same dialect called “Hassaniya” derived
from a Berber-influenced Arabic language, while each of Black African ethnic groups has its own
language and cultural specificities [24]. Inter-ethnic marriages are rare in Mauritania.
Blood collection and detection of G6PD deficiency
Between May and December 2016, whole blood was collected in a 5-ml ethylenediaminetetra-
acetic acid (EDTA)-coated blood collection tube from 454 healthy blood donors and was
immediately used for G6PD deficiency screening using CareStart rapid diagnostic test (Access-
Bio, Somerset, NJ, USA) according to the manufacturer’s instructions. About 200 μl of the
remaining blood were spotted on Whatman 3MM filter paper for storage and DNA extraction.
DNA extraction and detection of G6PD allelic variants
DNA was extracted from samples with G6PD deficiency using Quick-DNA Miniprep Plus kit
(Zymo Research Corporation, Irvine, CA, USA) according to the manufacturer’s instructions.
G6PD variants were characterized using DiaPlexC G6PD genotyping kit (SolGent Co., Dae-
jeon, Republic of Korea). The kit provides a simple and rapid alternative to PCR and enzyme
digestion-based assays and enables to detect six different g6pd point mutations by a one-step
multi-allelic specific PCR [10, 25]: G202A (Val-to-Met substitution in exon 4), A376G (Asn-
to-Asp substitution in exon 5), A542T (Asp-to-Val substitution in exon 6), C563T (Ser-to-Phe
substitution in exon 6), G680T (Arg-to-Leu substitution in exon 7), and T968C (Leu-to-Pro
substitution in exon 9). These mutations are associated with three levels of deficiency accord-
ing to the severity of clinical symptoms that may occur in the presence of stressors [10, 26]:
class II (severe deficiency; Mediterranean B-, C563T single mutation; Santamaria, A376G
+ A542T double mutations), class III (mild to moderate deficiency; A-(202), G202A + A376G
double mutations; A-(680), A376G + G680T double mutations; A-(968) Betica-Selma, A376G
+ T968C double mutations), and class III-IV (mild deficiency; type A, A376G single
mutation).
G6PD deficiency and associated genetic variants in Mauritania
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Two microliters of total genomic DNA (25–50 ng) were added to 23 μl of master mixture
containing pre-mix (12.5 μl), G6PD primer mixture (2 μl; African type), and nuclease-free
ultrapure water (8.5 μl), as recommended by the manufacturer. PCR was performed for 30
cycles at an annealing temperature of 60˚C, as recommended by the manufacturer. PCR prod-
ucts were analyzed by electrophoresis on 3% agarose gel, stained with GelGreen Nucleic Acid
Gel Stain (Biotium Inc., Fremont, CA, USA), and visualized under ultraviolet illumination.
The following sizes of PCR products were obtained, depending on the presence of mutations:
A376G, 103 bp; G202A, 157 bp; A542T, 241 bp; C563T, 220 bp; G680T, 388 bp; and T968C,
463 bp. The validity of each PCR amplification was confirmed by an internal control (947 bp).
PCR was performed in a thermal cycler Eppendorf MasterCycler Personal (Eppendorf, Ham-
burg, Germany).
Data analysis
Data were analyzed using MedCalc statistical software version 16.4.3 [27]. The chi-square test
was used for comparison of proportions. The significance level was set at P< 0.05.
Fig 1. Study site for the investigation of G6PD deficiency in Mauritania (red box). Inset map shows location of Mauritania in
Africa. This map was created using Microsoft Paint application (Redmond, WA).
https://doi.org/10.1371/journal.pone.0220977.g001
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Ethical approval
The study obtained ethical clearance from the ethical committee of the University of Nouak-
chott Al-Aasriya, and written informed consent was obtained from all participants.
Results
Characteristics of the study population
Overall, 454 unrelated individuals were enrolled during the study period. Data from 11 donors
(2.4%) were excluded from analysis due to missing data (5 without ethnic origin, 2 without
gender, 4 invalid G6PD screening tests). Data from the remaining 443 individuals were ana-
lyzed. Table 1 summarizes the characteristics of the study population. The median (range;
interquartile range) age was 30 (18–61; 12) years. Individuals under 18 years old were not rep-
resented in our sample population as the lower age limit for blood donation in the country is
18 years. The proportion of male donors (416/443; 94%) was significantly higher (P< 0.0001)
than that of females (27/443; 6%). All ethnic groups in Mauritania were represented in the
study population (168 white Moors, 173 black Moors, 100 Black Africans, and 2 mixed ethnic
origins). The proportion of white and black Moors in the study population did not differ sig-
nificantly (P = 0.85).
Prevalence of G6PD deficiency
Among 443 screened study subjects, 50 (11.3%) were phenotypically deficient for G6PD using
CareStart rapid diagnostic test (Table 1). G6PD deficiency was found, with no significant dif-
ferences, in 49 of 416 (11.8%) males and 1 of 27 (3.7%) females (χ2 = 1.6; df = 1; P = 0.8). The
Table 1. Demographic characteristics and G6PD-deficient phenotypes using Carestart rapid diagnostic test in
healthy blood donors in Nouakchott, Mauritania.
Characteristics N (%)
Total number of individuals 443
Gender
Male 416 (94)
Female 27 (6)
Ethnic group
White Moors 168 (38)
Black Moors 173 (39)
Black Africans� 100 (22.5)
Mixed 2 (0.5)
G6PD phenotype
Deficient 50 (11.3)
Normal 393 (88.7)
Deficient, men 49 (11.8)
Deficient, woman 1 (3.7)
G6PD deficiency and ethnic groups
White Moors 10 (5.9)
Black Moors 25 (14.4)
Black Africans�� 15 (15)
�Pular, Soninke and Wolof;
��12 Pulars and 3 Soninkes
https://doi.org/10.1371/journal.pone.0220977.t001
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prevalence of G6PD deficiency by ethnic groups indicated that Black Africans (15/100, 15.0%)
and black Moors (25/173; 14.4%) had similar frequencies of G6PD deficiency (P = 0.89). Com-
pared to these two ethnic groups, the prevalence of G6PD deficiency in white Moors was 5.9%
(10/168; P = 0.009). Of 50 G6PD-deficient blood donors, 13 (26%) reported that they had a
past history of malaria but were not able to remember the Plasmodium species and treatment
they received.
Identification of G6PD allelic variants
G6PD allelic variants were assessed in 45 (44 men and 1 woman) of 50 phenotypically G6PD-
deficient individuals. PCR failed in 5 of 50 samples, probably due to poor storage conditions
leading to DNA degradation. G6PD variant A (376G), characterized by little or no clinical sig-
nificance, was observed in three individuals (two men and one woman) and was associated
with a faint color change in CareStart rapid diagnostic test. Table 2 summarizes the results of
molecular analysis in 44 phenotypically G6PD-deficient males. The most commonly observed
G6PD allelic variant among G6PD deficient men was the moderate African variant A- (202A/
376G) in 14 of 44 (31.8%) individuals. Although the sample size was small, the African variant
A- was observed more frequently in Black Moors than the other ethnic groups (10 Black
Moors vs. 3 Black Africans and 1 White Moor). By contrast, in this small sample of G6PD-defi-
cient Mauritanians, the severe Mediterranean variant B- (563T) was observed in 13 of 44
(29.5%) subjects and occurred more frequently in White Moors (8 White Moors vs. 3 Black
Moor and 2 Black Africans). The moderate A- (376G/968C) allelic variant (also known as
Betica-Selma) was observed in 6 of 44 (13.6%) (5 Black Africans and 1 Black Moor) G6PD-
deficient subjects. The severe Santamaria variant A- (376G/542T) was observed in only one
White Moor. None of the expected allelic variants detectable by DiaPlexC G6PD genotyping
kit was observed in 8 (18.2%) of the tested phenotypically G6PD deficient men from two dif-
ferent ethnic groups (5 Black Moors and 3 Black Africans). The allelic variant G680T was not
found in our study population.
Discussion
In countries where P. vivax is endemic, primaquine and more recently tafenoquine remain the
only 8-aminoquinoline antimalarial drugs available for radical treatment. In Mauritania, sev-
eral studies have confirmed that P. vivax is endemic in the northern Saharan zone, including
Table 2. G6PD allelic variants among phenotypically deficient male blood donors by ethnic group in Nouakchott, Mauritania.
G6PD allelic variant� Common name Ethnic group Total (%)
White Moors Black Moors Black Africans��
Single 376G A 0 2 0 2 (4.5)
563T Mediterranean (B-) 8 3 2 13 (29.5)
Double 202A/376G African (A-) 1 10 3 14 (31.8)
376G/968C Betica-Selma 0 1 5 6 (13.6)
376G/542T Santamaria 1 0 0 1 (2.3)
Uncharacterized��� 0 5 3 8 (18.2)
Total 10 21 13 44 (100.0)
�PCR failed in samples from 5 phenotypically G6PD-deficient males, most probably due to DNA degradation;
�� 11 Pular and 2 Soninke;
���None of the six tested allelic variants was detected in these individuals with phenotypic deficiency although the internal control was positive. The only woman with
G6PD deficiency had G6PD A (376G) genotype. G680T was not found.
https://doi.org/10.1371/journal.pone.0220977.t002
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Nouakchott [1–3]. White Moorish individuals are more susceptible to P. vivax infection than
other ethnic groups, probably due to the high prevalence of positive Duffy blood group among
them, even though P. vivax was also found in few Duffy-negative patients [1, 28, 29]. Prima-
quine was introduced in the national malaria treatment guideline in 2014 for the control and
elimination of P. vivax malaria. At present, artemisinin-based combination therapy (ACT) is
the first-line drug to treat P. falciparum and P. vivax malaria. Primaquine administration has
not been implemented in the country owing to concerns about its potential toxicity, including
hemolytic anemia, in G6PD-deficient patients and the absence of a prior routine G6PD defi-
ciency testing for the safe use of primaquine at health facilities.
In the present study, G6PD deficiency was investigated in blood donors living in Nouak-
chott, an endemic area of P. vivax in Mauritania. Our results showed that the prevalence of
phenotypic G6PD deficiency using CareStart rapid diagnostic test is 11.3%. The mean preva-
lence of G6PD deficiency among countries with ongoing malaria transmission is estimated to
be 8% [9, 30]. The prevalence of G6PD deficiency reported in the present study is similar to
those reported from other West African countries, such as Senegal (12%) [31], Sierra Leone
(11.3%) [32] and Burkina Faso (9.5%) [33]. On the other hand, the prevalence of G6PD defi-
ciency in Mauritania is higher than that reported in North African countries, such as Tunisia
(4.4%), Algeria (5.4%), and Egypt (5.9%) [34, 35]. However, comparison of the frequency of
G6PD deficiency (5.9%) in White Moors of Arab descent and that of the dominant Arab ethnic
groups in Tunisia and Algeria reveals comparable results.
The study also revealed that the most common G6PD variants were G6PD A- (African vari-
ant) and G6PD B- (Mediterranean variant) found in 31.8% and 29.5% of G6PD-deficient
blood donors, respectively. G6PD A- and G6PD B- are among the most common G6PD vari-
ants worldwide. They may be associated with different severity of clinical symptoms in the
presence of antimalarial drugs such as primaquine, ranging from moderate (for G6PD A-) to
severe (for G6PD B-) anemia. In sub-Saharan Africa, G6PD A- (202A/376G) variant is the
most common variant [14]. For instance, in Burkina Faso, A- (202A/376G) was the only vari-
ant observed [33]. In Mali, A- (202A/376G) was also observed but the differences in propor-
tions between ethnic groups were not significant [36]. In some Arab African countries like
Algeria and Tunisia, the frequency of G6PD A- was as high as 46% [12, 35]. Inversely, in Sene-
gal and The Gambia, A- (376G/968C) was the most frequent allele associated with G6PD defi-
ciency, with the prevalence of 10% and 7%, respectively [31, 37, 38]. The Mediterranean G6PD
variant has not yet been described in sub-Saharan Africa, but it is the second most common
variant in Algeria (23%) and Tunisia (33.1%) [12,35].
Eight of 44 phenotypically deficient male blood donors showed none of the six expected
mutations. One possible explanation is that G6PD deficiency in these ethnically different indi-
viduals is associated with other variants not detected using DiaPlexC G6PD genotyping kit
and that the observed phenotype could be associated with different G6PD genotypes. Only
sequencing of g6pd gene in these individuals could provide further information. In Tunisia, no
mutation was identified in 6 of 56 (10.7%) G6PD-deficient screened subjects using PCR-
restriction fragment length polymorphism (RFLP) [39]. It is also possible that 8 G6PD-defi-
cient subjects whose genotype was not characterized in our study could be false positives, but
due to insufficient resources, we were not able to test the performance of CareStart rapid diag-
nostic test compared to the gold standard. Other studies have reported that diagnostic perfor-
mance of CareStart rapid diagnostic test is high compared to other existing rapid diagnostic
tests, and that this rapid diagnostic test is considered as a promising tool for point-of-care use
in countries with poor resources [40–43]. In the previous studies, the sensitivity and specificity
of CareStart rapid diagnostic test, compared to the reference quantitative spectrophotometric
method, were 85–100% and 72–99%, respectively, at the threshold of 30% of normal G6PD
G6PD deficiency and associated genetic variants in Mauritania
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activity [40–45]. Low sensitivity (62–68%) was reported in two studies, but the source of these
discrepant results was due to the misinterpretation of faint color change which, if corrected,
would have increased the sensitivity [46–48]. These data lend support to the view that this
rapid diagnostic test may become an indispensable tool to screen P. vivax-infected patients
before primaquine is administered.
Overall, the present study revealed heterogeneous prevalence of both African and Mediter-
ranean variants of G6PD deficiency using phenotypic and molecular tests among study sub-
jects belonging to different ethnic groups present in Mauritania. These findings were
somewhat expected because Mauritania is located at the intersection between Maghreb and
sub-Saharan African countries, and its ethnic composition is made up of Moors of Arab
descent, in whom Mediterranean G6PD variant B- (563T) predominates, and black Africans in
whom G6PD deficiency is mostly due to G6PD A- variant.
The main limitation of the present study was the inability to link the observed phenotypic
and genotypic G6PD deficiency with enzymatic activity determined by a reference method in
the study population. Moreover, despite the fact that 454 healthy individuals were recruited,
the sample size of the present study does not have an adequate power to compare differences
according to sex, ethnicity, and genotyping data. Nonetheless, to our knowledge, this is the
first report on the prevalence of G6PD deficiency and its molecular variants in Mauritania.
Further genotyping studies are needed to confirm the presence of additional variants that may
be associated with G6PD deficiency and determine further the frequencies of mutations in
G6PD in the general population as well as in different ethnic groups in relation to P. vivax
infection. Accurate and up-to-date mapping of the prevalence of G6PD deficiency and its vari-
ants is required to design appropriate strategies of P. vivax malaria elimination that includes
mass administration of primaquine.
Conclusion
The observed prevalence of G6PD deficiency and molecular variants are in agreement with
those observed in West and North African populations. The study highlights the need to
implement adequate G6PD deficiency screening with a reliable rapid diagnostic method before
prescribing primaquine for the radical treatment of P. vivax-infected patients in Mauritania to
minimize the risk of clinically relevant and severe hemolytic anemia associated with different
G6PD variants in the country. More studies on a larger population size, including a higher
number of women, are being planned in areas where P. vivax transmission occurs in the coun-
try. Further evaluation of quantitative rapid diagnostic tests for G6PD is warranted, especially
for females in whom the random X chromosome inactivation may affect the interpretation of
qualitative tests.
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